Next Article in Journal
Monoclonal Antibodies in Multiple Sclerosis: Present and Future
Previous Article in Journal
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview

Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease

1
Research Centre, Royal Perth Hospital, Perth, WA 6000, Australia
2
Dobney Hypertension Centre, School of Biomedical Science—Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6000, Australia
3
Dobney Hypertension Centre, School of Medicine—Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6000, Australia
4
Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth, WA 6000, Australia
*
Author to whom correspondence should be addressed.
Biomedicines 2019, 7(1), 19; https://doi.org/10.3390/biomedicines7010019
Received: 22 February 2019 / Revised: 8 March 2019 / Accepted: 10 March 2019 / Published: 13 March 2019
(This article belongs to the Special Issue The Interleukin-6 Family in Disease Pathogenesis and Therapy)
  |  
PDF [1209 KB, uploaded 27 March 2019]
  |     |  

Abstract

Healthy kidneys are important for the efficient regulation of metabolism. However, there is an ever increasing population of patients suffering from both acute and chronic kidney diseases that disrupt this homeostasis. This review will explore the emerging roles that interleukin 6 (IL-6) cytokine family members play in the pathogenesis of kidney disease. The IL-6 family of cytokines are involved in a diverse range of physiological functions. In relation to kidney disease, their involvement is no less diverse. Evidence from both preclinical and clinical sources show that IL-6 cytokine family members can play either a deleterious or protective role in response to kidney disease. This appears to be dependent on the type of kidney disease in question or the specific cytokine. Current attempts to use or target IL-6 cytokine family members as therapies of kidney diseases will be highlighted throughout this review. Finally, the involvement of IL-6 cytokine family members in kidney disease will be presented in the context of three regularly overlapping conditions: obesity, hypertension and diabetes. View Full-Text
Keywords: IL-6; kidney disease; cytokines; pre-clinical studies IL-6; kidney disease; cytokines; pre-clinical studies
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Magno, A.L.; Herat, L.Y.; Carnagarin, R.; Schlaich, M.P.; Matthews, V.B. Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease. Biomedicines 2019, 7, 19.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top